Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Incyte falls on Reverset Phase IIb data

July 26, 2005 12:28 AM UTC

INCY dropped $1.34 (15%) to $7.42 on 9.3 million shares on Monday after reporting results from a Phase IIb (Study 203) trial of Reverset to treat HIV patients who were failing their current treatment ...